US-based biotechnology companies Bluebird Bio and Gritstone Oncology have entered into strategic collaboration for the development of new cancer cell therapies.
Gritstone Oncology, the immuno-oncology upstart that has pocketed more than $194 million in venture capital, is going public. The Bay Area biotech is looking to raise up to $80 million in its IPO........